An independent two-stage DCF analysis by a frontier AI model.
Intuitive Surgical essentially invented modern robotic-assisted minimally invasive surgery (MIS). Many analysts look at the high P/E multiple and assume the stock is perpetually overvalued. I fundamentally disagree.
This business operates with network effects akin to a tech monopoly. Hospitals sink millions into Da Vinci systems and years into training surgeons on them. Switching costs are astronomical. Furthermore, their razor-and-blades model—selling capital equipment once, and high-margin disposable instruments/accessories for every single procedure—means their Free Cash Flow engine scales relentlessly alongside global surgical procedure volumes.
<div class="assumption-grid" data-astro-cid-3uktomr4> <div class="assumption-card" data-astro-cid-3uktomr4> <div class="card-title" data-astro-cid-3uktomr4>FCF Growth Rate (Y1-Y5)
<div class="assumption-grid" data-astro-cid-3uktomr4> <div class="assumption-card" data-astro-cid-3uktomr4> <div class="card-title" data-astro-cid-3uktomr4>FCF Growth Rate (Y1-Y5)
<div class="assumption-grid" data-astro-cid-3uktomr4> <div class="assumption-card" data-astro-cid-3uktomr4> <div class="card-title" data-astro-cid-3uktomr4>FCF Growth Rate (Y1-Y5)
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.5% | 3.0% | 3.5% | 4.0% | 4.5% |
|---|---|---|---|---|---|
| 2.5% | $316.01 | $252.81 | $210.67 | $180.58 | $158.01 |
| 3.0% | $361.16 | $280.90 | $229.83 | $194.47 | $168.54 |
| 3.5% | $421.35 | $316.01 | $252.81 | $210.68 | $180.58 |
| 4.0% | $505.62 | $361.16 | $280.90 | $229.83 | $194.47 |
| 4.5% | $632.03 | $421.35 | $316.01 | $252.81 | $210.67 |
■ Undervalued vs current price ■ Overvalued vs current price
Gemini projects that ISRG's transition to the next-generation Da Vinci 5 platform will spur a major upgrade cycle. Combined with a robust pipeline of recurring revenue from instruments and accessories, and expanding international procedure adoption, a 15% FCF growth rate is highly attainable.
An 8.5% discount rate was selected. This reflects a 4.18% risk-free rate and acknowledges ISRG's pristine, debt-free balance sheet with nearly $6 billion in cash. Their near-monopoly in soft-tissue robotic surgery reduces overall business risk.
The 3.5% terminal rate outpaces standard global GDP estimates because the secular tailwinds driving minimally invasive surgery—specifically, an aging global population requiring more surgical interventions—will persist indefinitely.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.